Last reviewed · How we verify
Remicade biosimilars
17 approved
0 filed
6 Phase 3
All key patents expired
About Remicade
Remicade (INFLIXIMAB) — originally marketed by Johnson & Johnson. Class: Tumor Necrosis Factor Blocker [EPC]. Target: Tumor necrosis factor. Area: Oncology. First approved 1998-01-01.
Approved biosimilars (17)
| Biosimilar | Sponsor | Phase | First approval | Country |
|---|---|---|---|---|
| Remicade | Johnson & Johnson | marketed | 1998-01-01 | |
| infliximab, etanercept, adalimumab | University Hospital, Strasbourg, France | marketed | ||
| Infliximab, methylprednisolone, methotrexate | Université Catholique de Louvain | marketed | ||
| Infliximab Adalimumab y Golimumab | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | marketed | ||
| Infliximab CT-P13 | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | marketed | ||
| Infliximab and immunosuppressives | Children's Hospital of Fudan University | marketed | ||
| Infliximab (Remicade) | University of California, San Diego | marketed | ||
| Infliximab-Innovator | Onze Lieve Vrouwe Gasthuis | marketed | ||
| Infliximab [infliximab biosimilar 3] | Pfizer | marketed | ||
| AVSOLA | AMGEN INC | marketed | ||
| RENFLEXIS | SAMSUNG BIOEPIS CO LTD | marketed | ||
| infliximab+azathioprine | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | marketed | ||
| Infliximab and MTX | Chinese University of Hong Kong | marketed | ||
| Infliximab biosimilar | Hanyang University Seoul Hospital | marketed | ||
| infliximab therapeutic drug monitoring | Imelda GI Clinical Research Center | marketed | ||
| Infliximab-Dyyb | Asan Medical Center | marketed | ||
| IXIFI | PFIZER INC | marketed |
Filed biosimilars under regulatory review (0)
Phase 3 biosimilars (6)
| Biosimilar | Sponsor | Phase | First approval | Country |
|---|---|---|---|---|
| Infliximab (IFX alone) | Children's Memorial Health Institute, Poland | phase 3 | ||
| infliximab infusion; AZA placebo caps | Centocor Ortho Biotech Services, L.L.C. | phase 3 | ||
| infliximab, etanercept | Centocor Ortho Biotech Services, L.L.C. | phase 3 | ||
| Infliximab plus methotrexate | Helsinki University Central Hospital | phase 3 | ||
| Infliximab (INF) + MTX, DB | Bristol-Myers Squibb | phase 3 | ||
| Infliximab subcutaneous | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | phase 3 |
Originator patent timeline
Active patents (0)
Expired patents (0)
Subscribe to biosimilar updates
Every regulatory action on Remicade or any of its biosimilars: